HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2008.104497v1 54/10/1617    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, J.-M. Articles by Ladenson, J. H. Search for Related Content PubMed PubMed Citation Articles by Lee, J.-M. Articles by Ladenson, J. H.

The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients

¹ Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;² The Hope Center for Neurological Disorders and the Department of Neurology, Washington University School of Medicine, St. Louis, MO;³ Division of Biostatistics, Washington University School of Medicine, St. Louis, MO;⁴ Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden;⁵ Memory Clinic, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden.

^aAddress correspondence to this author at: Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8118, St. Louis, MO 63110. Fax # 314-454-5208; e-mail ladenson{at}wustl.edu.

background: Definitive diagnosis of Alzheimer disease (AD) can be made only by histopathological examination of brain tissue, prompting the search for premortem disease biomarkers. We sought to determine if the novel brain injury biomarker, visinin-like protein 1 (VLP-1), is altered in the CSF of AD patients compared with controls, and to compare its values to the other well-studied CSF biomarkers 42-amino acid amyloid-β peptide (Aβ_1–42), total Tau (tTau), and hyperphosphorylated Tau (pTau).

methods: Using ELISA, we measured concentrations of Aβ_1–42, tTau, pTau, and VLP-1 in CSF samples from 33 AD patients and 24 controls. We compared the diagnostic performance of these biomarkers using ROC curves.

results: CSF VLP-1 concentrations were significantly higher in AD patients [median (interquartile range) 365 (166) ng/L] compared with controls [244 (142.5) ng/L]. Although the diagnostic performance of VLP-1 alone was comparable to that of Aβ, tTau, or pTau alone, the combination of the 4 biomarkers demonstrated better performance than each individually. VLP-1 concentrations were higher in AD subjects with APOE 4/4 genotype [599 (240) ng/L] compared with 3/4 [376 (127) ng/L] and 3/3 [280 (115.5) ng/L] genotypes. Furthermore, VLP-1 values demonstrated a high degree of correlation with pTau (r = 0.809) and tTau (r = 0.635) but not Aβ_1–42 (r = –0.233). VLP-1 was the only biomarker that correlated with MMSE score (r = –0.384, P = 0.030).

conclusions: These results suggest that neuronal injury markers such as VLP-1 may have utility as biomarkers for AD.

The following articles in journals at HighWire Press have cited this article:

				H.-G. Bernstein and K.-H. Braunewell Some Notes on Visinin-Like Protein 1 and Alzheimer Disease Clin. Chem., May 1, 2009; 55(5): 1041 - 1043. [Full Text] [PDF]

				M. M. Verbeek and M. G.M. Olde Rikkert Cerebrospinal Fluid Biomarkers in the Evaluation of Alzheimer Disease Clin. Chem., October 1, 2008; 54(10): 1589 - 1591. [Full Text] [PDF]